STERIS plc is a key player in the infection prevention industry, offering a wide range of products and services globally. The company leads innovation in healthcare, sterilization technologies, and life sciences. Investors consider STE a reliable choice due to its consistent performance across key financial metrics.
STERIS plc displays a strong financial performance, earning an 'A-' rating with steady scores across multiple metrics.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 4 | |
| Return on Assets | 5 | |
| Debt to Equity | 2 | |
| Price to Earnings | 2 | |
| Price to Book | 2 |
The historical data reflects consistent performance, with minor variations in key scores.
| Date | Overall Score | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-06-29 | 4 | 5 | 4 | 5 | 2 | 2 | 2 |
| Previous | 0 | 5 | 4 | 5 | 2 | 2 | 2 |
The consensus among analysts suggests a stable valuation, with a high degree of agreement on price targets.
| High | Low | Median | Consensus |
|---|---|---|---|
| 270 | 269 | 269.5 | 269.5 |
Analysts maintain a positive outlook on STERIS plc, with most recommendations favoring a 'Buy'.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 11 | |
| Hold | 2 | |
| Sell | 0 | |
| Strong Sell | 0 |
STERIS plc represents a solid investment opportunity within the healthcare industry. Its robust portfolio in infection prevention and life science solutions aligns with global healthcare needs, suggesting upward growth potential. However, market saturation and economic fluctuations present notable risks. Continued innovation and strategic market expansion are essential to sustaining its competitive edge. Overall, the investment outlook remains positive, with stable analyst confidence.
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.